Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- A Lilly-ImClone Deal May Offer the Drama that CEO Lechleiter Craves
- Today came the news that Eli Lilly is one of the mystery suitors in the ImClone deal that Bristol-Myers Squibb was just booted from. If CEO John Lechleiter were to scoop up ImClone -- thus bolting on the cancer specialist's pipeline to replace the absence of its...
- Blog posts 2008-09-29
Additional Resources
- Eli Lilly's Lechleiter Does Shameless U-turn on Payments to Doctors
- Eli Lilly CEO John Lechleiter has done a spectacular about-face on the issue of disclosing the drug company's payments to doctors. Last week he was against it. Today he's suddenly in favor of it. Let's be clear, Lechleiter is doing the right thing by creating "an online...
- Blog posts 2008-09-24
- Lilly CEO Lechleiter's Prasugrel Bet Appears to Pay Off
- A few months ago, BNET suggested that Eli Lilly's acquisition of ImClone was a hedge to give the company new revenue sources in the event that its application for blood thinner prasugrel was turned down by the FDA. An FDA panel today voted 9-0 to approve the...
- Blog posts 2009-02-03
- Lilly CEO Lechleiter and PhRMA's Boogeyman: a "Government-Run Plan"
- Get used to hearing this phrase in the debate over healthcare reform: "a government run-plan." That is the boogeyman that Eli Lilly CEO John Lechleiter used in his op-ed today in the Wall Street Journal to scare Americans away from universal healthcare coverage. by Jim Edwards
- Blog posts 2009-05-15
- Eli Lilly Q2 2007 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions And our first question comes from the line of James Kelly of Goldman Sachs. Please go ahead. James Kelly - Goldman Sachs Thank you and good morning. My question relates to Zyprexa and the depot formulation, and thank you for the additional data in Canada...
- Earnings calls 2007-07-24
- Eli Lilly Execs Receive $48 Million in Pay; Plus Chairman Taurel Adds $40 Million Nest Egg
- The top six executives at Eli Lilly received $48 million in pay between them in 2008, according to the Indianapolis Star. CEO John Lechleiter received $13 million last year, a 39 percent increase from the year before. Chairman emeritus Sidney Taurel got $13 million, too. ...
- Blog posts 2009-02-10
- Big Pharma Maintains Illusion of Innovation
- Wall Street Weather submits: Eli Lilly LLY Chairman and CEO John Lechleiter’s op-ed piece on “Health-Care Reform and the ‘Innovation Test’” in yesterday’s Wall Street Journal is yet another anti-consumer big pharma industry rant. Mr. Lechleiter does not want Americans to have the ability to choose between a public or...
- External links 2009-05-15
- Eli Lilly & Co. Q1 2008 Earnings Call Transcript
- Question-and-Answer SessionOur first question will come from the line Jim Kelly from Goldman Sachs. Please go ahead. James Kelly - Goldman Sachs Thank you, and good morning. I have a question about the impact in volumes, just taking a look at the comparison from the last quarterly report, where...
- Earnings calls 2008-04-21
- Lechleiter named Eli Lilly and Co. COO
- Eli Lilly and Co. promoted John C. Lechleiter president and chief operating officer.
- Research articles 2005-11-01
- In Light of Prasugrel Delay, Lilly-ImClone Deal Suddenly Makes Sense
- For those of you wondering why Eli Lilly would volunteer to have its stock crushed by the loss of cash and added debt required to buy ImClone, here's one idea: The deal makes more sense if Lilly believes that prasugrel -- a potential blockbuster blood thinner with the brand name...
- Blog posts 2008-10-17
- Odds Improve for Lilly's Prasugrel-ImClone Gamble
- A panel of the European Medicines Agency recommended the approval of prasugrel, Eli Lilly's new blood thinner, and such recommendations are usually followed by the agency within a couple of months, Reuters reports. The news is a significant win in Lilly's long campaign to get this drug to market. It...
- Blog posts 2008-12-19
- The War for Amylin: Lilly Not Interested; Icahn Calls the Company a "Dictatorship"
- Eli Lilly CEO John Lechleiter complicated the battle for Amylin today by telling Reuters he was not interested in buying the company. It was widely suspected that investor Carl Icahn, who is in a three-way war for control of Amylin's board of directors, wants to dress up...
- Blog posts 2009-04-28
- Eli Lilly Q3 2007 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions Our first question comes Roopesh Patel with UBS please go ahead. Roopesh Patel - UBS Thank you. I have a couple of questions, first on Cymbalta. In light of the recent slowdown in market share trends over the past five months, I was just wondering,...
- Earnings calls 2007-10-18
- Eli Lilly & Co. Q2 2008 Earnings Call Transcript
- Question-and-Answer SessionOperator Thank you. [Operator Instructions]. First question, James Kelly, Goldman Sachs. Please go ahead, sir. James Kelly - Goldman Sachs Great, thank you, and good morning. My first question -- my question really has to do with, and thank you for the comments on the Alzheimer’s program, John,...
- Earnings calls 2008-07-24
- Eli Lilly & Co. Q4 2008 Earnings Call Transcript
- Question-and-Answer SessionOperator Thank you. Operator Instructions. Our first question comes from the line Tim Anderson with Sanford Bernstein. Please go ahead. Jay Olsen - Sanford Bernstein Good morning, this is Jay Olsen for Tim Anderson. I have two questions. First, can you update us on what impact you might...
- Earnings calls 2009-01-29
- Even Lists Can Hold Valuable Lessons
- Fortune further solidifies its position as the oft-disputed but never displaced champion of listing, ranking and corporate back-patting in a good way this time with today’s story, “How Top Companies Breed Starsâ€. Senior editor Geoff Colvin and a team of reporters worked with a pair of consulting firms to come...
- Blog posts 2007-09-20
- Eli Lilly announces sales realignment
- ELI LILLY president and COO John Lechleiter said the drug maker will undergo "a sales force realignment" that will mean no new additions to its sales force in the immediate future.
- Research articles 2006-01-01
- Lilly and GSK Emit Smoke, But No Fire, In Massachusetts Legal Flap
- Eli Lilly CEO John Lechleiter pictured has joined the bizarre political pantomime surrounding the new Massachusetts law requiring drug companies to detail the payments they make to doctors. He told the Boston Business Journal: Life sciences investment will be scared away ... [the law has the potential to] subject...
- Blog posts 2008-09-22
- Eli Lilly & Co. Q4 2007 Earnings Call Transcript
- Question-and-Answer SessionThank you. [Operator Instructions]. Our first question is from the line of David Risinger from Merrill Lynch. Please go ahead. David Risinger - Merrill Lynch Yes, thanks very much. Thank you for all the detail on the financial results. Just looking forward to next week, could you please...
- Earnings calls 2008-01-29
- Eli Lilly Q2 2007 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions And our first question comes from the line of James Kelly of Goldman Sachs. Please go ahead. James Kelly - Goldman Sachs Thank you and good morning. My question relates to Zyprexa and the depot formulation, and thank you for the additional...
- Earnings calls 2007-07-24
- << Previous
- page 1 of 1
- Next >>
